The market launch of Ypsomed’s OptiClik is a major milestone for the Switzerland-based company. The product itself is the world’s first semi-disposable pen system, containing both reusable and disposable modules.
Ypsomed’s CEO, Matthew Robin, has stressed the benefits of the launch, commenting, “Ypsomed will greatly benefit for two reasons: firstly, Lantus is enjoying ongoing strong growth and secondly, the market penetration of insulin pen systems in the US market is still very low at around 12% and expected to grow significantly over the next years.”
The OptiClik pen will also enable Sanofi-Aventis to increase its market share of Lantus, the leading long-lasting insulin in the US diabetes market.
Innovative devices and systems enabling patients to inject drugs themselves (medical selfcare solutions) are increasingly popular as they can contribute to ensuring therapeutic success whilst simultaneously working to improve the patient’s quality of life.